G Protein-Coupled Receptor 87 (GPR87) Promotes the Growth and Metastasis of CD133+ Cancer Stem-Like Cells in Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Yan, Mingxia ^a   Li, Hong ^a   Zhu, Miaoxin ^a   Zhao, Fangyu ^a   Zhang, Lixing ^a   Chen, Taoyang ^b   Jiang, Guoping ^c   Xie, Haiyang ^c   Cui, Ying ^d   Yao, Ming ^a   Li, Jinjun ^a  

^a SHANGHAI CANCER INSTITUTE   (China)

^b Qi Dong Liver Cancer Institute   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d Guangxi Cancer Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 87; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SELECTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAGNETIC ACTIVATED CELL SORTING; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ANTIGENS, CD; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PEPTIDES; POLYMERASE CHAIN REACTION; RECEPTORS, LYSOPHOSPHATIDIC ACID;

EID: 84876061587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061056     Document Type: Article

References (33)

1. Zhu LF, Hu Y, Yang CC, Xu XH, Ning TY, et al. (2012) Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Lab Invest 92: 744-752.
2. Zhang J, Luo N, Luo Y, Peng Z, Zhang T, et al. (2012) microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol 40: 747-756.
3. Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, et al. (2011) Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117: 2970-2985.
4. Hayashi T, Ding Q, Kuwahata T, Maeda K, Miyazaki Y, et al. (2012) Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. Cancer Sci 103: 889-896.
5. Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C, (2012) Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol 227: 2947-2952.
6. Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, et al. (2010) Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 31: 1376-1380.
7. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, et al. (2009) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446-453.
8. Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M, et al. (2009) Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci 13Suppl 1: 55-62.
9. Yang Z, Zhang L, Ma A, Liu L, Li J, et al. (2011) Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 6: e28405.
10. Shi L, Wan Y, Sun G, Gu X, Qian C, et al. (2012) Functional Differences of miR-125b on the Invasion of Primary Glioblastoma CD133-Negative Cells and CD133-Positive Cells. Neuromolecular Med 14: 303-316.
11. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
12. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820-824.
13. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY, (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
14. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2010) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707.
15. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, et al. (2012) CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55: 807-820.
16. Zhang Y, Scoumanne A, Chen X, (2010) G Protein-Coupled Receptor 87: a Promising Opportunity for Cancer Drug Discovery. Mol Cell Pharmacol 2: 111-116.
17. Glatt S, Halbauer D, Heindl S, Wernitznig A, Kozina D, et al. (2008) hGPR87 contributes to viability of human tumor cells. Int J Cancer 122: 2008-2016.
18. Cotton M, Claing A, (2009) G protein-coupled receptors stimulation and the control of cell migration. Cell Signal 21: 1045-1053.
19. Malbon CC, (2005) G proteins in development. Nat Rev Mol Cell Biol 6: 689-701.
20. Wettschureck N, Offermanns S, (2005) Mammalian G proteins and their cell type specific functions. Physiol Rev 85: 1159-1204.
21. Zhang Y, Qian Y, Lu W, Chen X, (2009) The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res 69: 6049-6056.
22. Hu C, Li H, Li J, Zhu Z, Yin S, et al. (2008) Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29: 2289-2297.
23. Petersen BE, Zajac VF, Michalopoulos GK, (1998) Hepatic oval cell activation in response to injury following chemically induced periportal or pericentral damage in rats. Hepatology 27: 1030-1038.
24. Paku S, Nagy P, Kopper L, Thorgeirsson SS, (2004) 2-acetylaminofluorene dose-dependent differentiation of rat oval cells into hepatocytes: confocal and electron microscopic studies. Hepatology 39: 1353-1361.
25. Li Z, Chen J, Li L, Ran JH, Li XH, et al. (2012) Human hepatocyte growth factor (hHGF)-modified hepatic oval cells improve liver transplant survival. PLoS One 7: e44805.
26. Chen L, Kasai T, Li Y, Sugii Y, Jin G, et al. (2012) A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One 7: e33544.
27. Nakashima O, Kojiro M, (2001) Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 8: 404-409.
28. Wu CP, Zhou L, Xie M, Tao L, Zhang M, et al. (2011) [Isolation and in vitro characterization of CD133(+) side population cells from laryngeal cancer cell line]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 46: 752-757.
29. Dalerba P, Cho RW, Clarke MF, (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284.
30. Jordan CT, Guzman ML, Noble M, (2006) Cancer stem cells. N Engl J Med 355: 1253-1261.
31. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
32. You H, Ding W, Rountree CB, (2010) Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 51: 1635-1644.
33. Zhang L, Sun H, Zhao F, Lu P, Ge C, et al. (2012) BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res 72: 4276-4285.